Literature DB >> 26341741

Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor.

David Sanford1, Hagop Kantarjian1, Jeffrey Skinner1, Elias Jabbour1, Jorge Cortes2.   

Abstract

Entities:  

Keywords:  chronic myeloid leukemia; phase II; ponatinib; resistant; tyrosine kinase inhibitor

Mesh：

Substances：

Year:  2015        PMID： 26341741      PMCID： PMC4666339          DOI： 10.3324/haematol.2015.132845

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  6 in total

1.  Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.

Authors:  Neil P Shah; François Guilhot; Jorge E Cortes; Charles A Schiffer; Philipp le Coutre; Tim H Brümmendorf; Hagop M Kantarjian; Andreas Hochhaus; Philippe Rousselot; Hesham Mohamed; Diane Healey; Michael Cunningham; Giuseppe Saglio
Journal:  Blood       Date:  2014-02-25       Impact factor: 22.113

2.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  J E Cortes; D-W Kim; J Pinilla-Ibarz; P le Coutre; R Paquette; C Chuah; F E Nicolini; J F Apperley; H J Khoury; M Talpaz; J DiPersio; D J DeAngelo; E Abruzzese; D Rea; M Baccarani; M C Müller; C Gambacorti-Passerini; S Wong; S Lustgarten; V M Rivera; T Clackson; C D Turner; F G Haluska; F Guilhot; M W Deininger; A Hochhaus; T Hughes; J M Goldman; N P Shah; H Kantarjian
Journal:  N Engl J Med       Date:  2013-11-01       Impact factor: 91.245

3.  Ponatinib in refractory Philadelphia chromosome-positive leukemias.

Authors:  Jorge E Cortes; Hagop Kantarjian; Neil P Shah; Dale Bixby; Michael J Mauro; Ian Flinn; Thomas O'Hare; Simin Hu; Narayana I Narasimhan; Victor M Rivera; Tim Clackson; Christopher D Turner; Frank G Haluska; Brian J Druker; Michael W N Deininger; Moshe Talpaz
Journal:  N Engl J Med       Date:  2012-11-29       Impact factor: 91.245

Review 4.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Authors:  Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

5.  Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.

Authors:  Carlo Gambacorti-Passerini; Tim H Brümmendorf; Dong-Wook Kim; Anna G Turkina; Tamas Masszi; Sarit Assouline; Simon Durrant; Hagop M Kantarjian; H Jean Khoury; Andrey Zaritskey; Zhi-Xiang Shen; Jie Jin; Edo Vellenga; Ricardo Pasquini; Vikram Mathews; Francisco Cervantes; Nadine Besson; Kathleen Turnbull; Eric Leip; Virginia Kelly; Jorge E Cortes
Journal:  Am J Hematol       Date:  2014-04-28       Impact factor: 10.047

6.  Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

Authors:  F J Giles; P D le Coutre; J Pinilla-Ibarz; R A Larson; N Gattermann; O G Ottmann; A Hochhaus; J P Radich; G Saglio; T P Hughes; G Martinelli; D-W Kim; S Novick; K Gillis; X Fan; J Cortes; M Baccarani; H M Kantarjian
Journal:  Leukemia       Date:  2012-07-05       Impact factor: 11.528
  6 in total
  6 in total

1.  Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase.

Authors:  Massimo Breccia; Elisabetta Abruzzese; Alessandra Iurlo; Antonella Gozzini; Alessandro Isidori; Domenica Gangemi; Patrizia Pregno; Giuliana Alimena
Journal:  Haematologica       Date:  2016-05-31       Impact factor: 9.941

Review 2.  Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.

Authors:  David Hurtado-de-Mendoza; Arturo Loaiza-Bonilla; Paula A Bonilla-Reyes; Gabriel Tinoco; Rodrigo Alcorta
Journal:  Cureus       Date:  2017-05-18

3.  Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer.

Authors:  Erdem Altunel; Roham S Roghani; Kai-Yuan Chen; So Young Kim; Shannon McCall; Kathryn E Ware; Xiling Shen; Jason A Somarelli; David S Hsu
Journal:  BMC Cancer       Date:  2020-06-24       Impact factor: 4.430

Review 4.  Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia.

Authors:  Matteo Molica; Emilia Scalzulli; Gioia Colafigli; Robin Foà; Massimo Breccia
Journal:  Ther Adv Hematol       Date:  2019-03-01

5.  Patient-derived xenografts and organoids model therapy response in prostate cancer.

Authors:  Sofia Karkampouna; Federico La Manna; Andrej Benjak; Mirjam Kiener; Marta De Menna; Eugenio Zoni; Joël Grosjean; Irena Klima; Andrea Garofoli; Marco Bolis; Arianna Vallerga; Jean-Philippe Theurillat; Maria R De Filippo; Vera Genitsch; David Keller; Tijmen H Booij; Christian U Stirnimann; Kenneth Eng; Andrea Sboner; Charlotte K Y Ng; Salvatore Piscuoglio; Peter C Gray; Martin Spahn; Mark A Rubin; George N Thalmann; Marianna Kruithof-de Julio
Journal:  Nat Commun       Date:  2021-02-18       Impact factor: 14.919

Review 6.  Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies.

Authors:  Fiona H Tan; Tracy L Putoczki; Stanley S Stylli; Rodney B Luwor
Journal:  Onco Targets Ther       Date:  2019-01-18       Impact factor: 4.147
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.